Corrects Q4 Operating Expenses figure in Key Details table to $48.18 mln from -$48.18 mln
Overview
Biopharmaceutical firm's Q4 2025 net revenue was $128.6 mln, driven by DefenCath sales
Q4 net income of $14 mln missed analyst expectations
Company announced $75 mln share repurchase program
Outlook
CorMedix expects 2026 net revenue between $300 mln and $320 mln
Company projects 2026 adjusted EBITDA between $100 mln and $125 mln
CorMedix anticipates Phase 3 ReSPECT study data in Q2 2026
Result Drivers
DEFENCATH SALES - Q4 net revenue of $128.6 mln largely driven by DefenCath sales, contributing $91.2 mln
MELINTA ACQUISITION - Melinta portfolio contributed $37.4 mln to Q4 revenue, marking first full quarter post-acquisition
INCREASED OPERATING EXPENSES - Q4 operating expenses rose to $48.2 mln, driven by Melinta acquisition costs and R&D investments
Company press release: ID:nGNX27NWYd
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 EPS | Miss | $0.16 | $0.82 (7 Analysts) |
Q4 Net Income | Miss | $14.02 mln | $68.24 mln (7 Analysts) |
Q4 Basic EPS | $0.18 | ||
Q4 Operating Expenses | $48.18 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for CorMedix Inc is $15.00, about 110.7% above its March 4 closing price of $7.12
The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 4 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments